UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C.  20549

                           FORM 10-QSB


[X]   QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
      ACT OF 1934

          For quarterly period ended September 30, 2004

[ ]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934


                  Commission File No.  000-30991

             SKINOVATION PHARMACEUTICAL INCORPORATED
   (Name of small business issuer as specified in its charter)


        NEVADA                                    87-0458170
  (State of incorporation)             (I.R.S. Employer Identification No.)

                      2157 S. Lincoln Street
                    Salt Lake City, Utah 84106
                          (801) 323-2395
  (Address and telephone number of principal executive offices)

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes [X]   No [  ]

As of October 20, 2004 Skinovation Pharmaceutical Incorporated had a total of
708,000 shares of common stock issued and outstanding.

Transitional small business disclosure format:  Yes [ ]  No [X]

<PAGE>


                        TABLE OF CONTENTS

                  PART I: FINANCIAL INFORMATION

Item 1.  Financial Statements............................................2

Item 2.  Plan of Operation ..............................................8

Item 3.  Controls and Procedures.........................................8

                    PART II: OTHER INFORMATION

Item 6.  Exhibits .......................................................9

Signatures...............................................................9




                 PART I:   FINANCIAL INFORMATION


ITEM 1. FINANCIAL STATEMENTS

The financial information set forth below with respect to our statements of
operations for the three and nine month periods ended September 30, 2004 and
2003 is unaudited.  This financial information, in the opinion of management,
includes all adjustments consisting of normal recurring entries necessary for
the fair presentation of such data.  The results of operations for the nine
month period ended September 30, 2004 are not necessarily indicative of
results to be expected for any subsequent period.



                                2

<PAGE>










             Skinovation Pharmaceutical Incorporated

                       Financial Statements

                        September 30, 2004








                                3

<PAGE>






                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                          Balance Sheets


                              ASSETS


                                                    September 30  December 31,
                                                        2004         2003
                                                   ------------- -------------
                                                    (Unaudited)
CURRENT ASSETS
  Cash                                             $      3,198  $          -
                                                   ------------- -------------

  TOTAL ASSETS                                     $      3,198  $          -
                                                   ============= =============


               LIABILITIES AND STOCKHOLDER' EQUITY

CURRENT LIABILITIES

Accounts Payable - Related party                   $     33,776  $     33,776
Advances Payable                                          5,000             -
                                                   ------------- -------------

  Total Liabilities                                      38,776        33,776
                                                   ------------- -------------
STOCKHOLDERS' EQUITY

Common Stock, $.001 par value;
  50,000,000 shares authorized;
  708,000 shares issued and outstanding                     708           708

Additional Paid in Capital                               25,148        25,148

Deficit Accumulated During the Development Stage        (61,434)      (59,632)
                                                   ------------- -------------

  Total Stockholders' Equity                            (35,578)      (33,776)
                                                   ------------- -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY       $      3,198  $          -
                                                   ============= =============



                                4

<PAGE>
<TABLE>
<CAPTION>

                         Skinovation Pharmaceutical, Inc.
                           (Development Stage Company)
                             Statement of Operations
                                   (Unaudited)



                                                                                       From
                               For the       For the       For the       For the       inception on
                               three months  three months  nine months   nine months   January 15,
                               ended         ended         ended         ended         1988
                               Sept. 30,     Sept. 30,     Sept. 30,     Sept. 30,     to Sept. 30
                               2004          2003          2004          2003          2004
                               ------------- ------------- ------------- ------------- -------------

                            <c>           <c>           <c>           <c>           <c>
REVENUES                       $          -  $          -  $          -  $          -  $     27,937
                               ------------- ------------- ------------- ------------- -------------
EXPENSES
  General & Administrative              496             -         1,802             -       126,446
                               ------------- ------------- ------------- ------------- -------------

    TOTAL EXPENSES                      496             -         1,802             -       126,446
                               ------------- ------------- ------------- ------------- -------------
NET LOSS BEFORE DISCONTINUED
  OPERATIONS                           (496)            -        (1,802)            -       (98,509)

GAIN ON DISPOSAL OF OPERATIONS            -             -             -             -        37,075
                               ------------- ------------- ------------- ------------- -------------

NET INCOME (LOSS)              $       (496) $          -  $     (1,802) $          -  $    (61,434)
                               ============= ============= ============= ============= =============

NET LOSS PER SHARE             $          -  $          -  $          -  $          -  $      (0.16)
                               ============= ============= ============= ============= =============
WEIGHTED AVERAGE SHARES
  OUTSTANDING                       708,000       708,000       708,000       708,000       374,116
                               ============= ============= ============= ============= =============




                                        5
</TABLE>
<PAGE>
<TABLE>
<CAPTION>



                         Skinovation Pharmaceutical, Inc.
                           (A Development Stage Company)
                             Statement of Cash Flows
                                   (Unaudited)


                                                                               From
                                                                               Inception on
                                                    For the nine months ended  January 15, 1988
                                                           September 30,       Through
                                                   --------------------------- September 30,
                                                     2004            2003      2004
                                                   ------------- ------------- --------------

                                                <c>           <c>           <c>

Cash Flows from Operating Activities

  Net Loss                                         $     (1,802) $          -  $     (61,434)
  Less  Non-cash Items:
  Shares issued for services                                  -             -         10,433
  Shares issued for debt payment                              -             -          1,424
  Increase in accounts payable                                -             -         33,776
  Loss on disposal of PP&E                                    -             -          5,263
                                                   ------------- ------------- --------------

  Net Cash Provided (Used) by Operating Activities       (1,802)            -        (10,538)
                                                   ------------- ------------- --------------
Cash Flows from Investing Activities
  Cash paid for PP&E                                          -             -         (5,264)
                                                   ------------- ------------- --------------

  Net Cash Provided (Used) by Investing Activities            -             -         (5,264)
                                                   ------------- ------------- --------------
Cash Flows from Financing Activities
  Cash received from advances                             5,000             -          5,000
  Cash paid for offering costs                                -             -         (7,000)
  Common stock issued for cash                                -             -         21,000
                                                   ------------- ------------- --------------

  Net Cash Provided (Used) by Financing Activities        5,000             -         19,000
                                                   ------------- ------------- --------------

Increase (Decrease) in Cash                               3,198             -          3,198

Cash and Cash Equivalents at Beginning of Period              -             -              -
                                                   ------------- ------------- --------------

Cash and Cash Equivalents at End of Period         $      3,198  $          -  $       3,198
                                                   ============= ============= ==============

Supplemental Cash Flow Information:

  Stock issued for debt payment                    $          -  $          -  $       1,424
  Stock issued for services                        $          -  $          -  $      10,433

  Cash Paid For:
    Interest                                       $          -  $          -  $           -
    Income Taxes                                   $          -  $          -  $           -




                                        8


</TABLE>
<PAGE>




             Skinovation Pharmaceutical Incorporated
                Notes to the Financial Statements
                        September 30, 2004


GENERAL
-------

Skinovation Pharmaceutical Incorporated (the Company) has elected to omit
substantially all footnotes to the financial statements for the nine months
ended September 30, 2004 since there have been no material changes (other than
indicated in other footnotes) to the information previously reported by the
Company in their Annual Report filed on the Form 10-KSB for the twelve months
ended December 31, 2003.

UNAUDITED INFORMATION
---------------------

The information furnished herein was taken from the books and records of the
Company without audit.  However, such information reflects all adjustments
which are, in the opinion of management, necessary to properly reflect the
results of the interim period presented.  The information presented is not
necessarily indicative of the results from operations expected for the full
fiscal year.



                                7
<PAGE>


In this report references to "Skinovation," "we," "us," and "our" refer to
Skinovation Pharmaceutical Incorporated.

        SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

The Securities and Exchange Commission ("SEC") encourages companies to
disclose forward-looking information so that investors can better understand
future prospects and make informed investment decisions.  This report contains
these types of statements.  Words such as "may," "will," "expect," "believe,"
"anticipate," "estimate," "project," or "continue" or comparable terminology
used in connection with any discussion of future operating results or
financial performance identify forward-looking statements.  You are cautioned
not to place undue reliance on the forward-looking statements, which speak
only as of the date of this report.  All forward-looking statements reflect
our present expectation of future events and are subject to a number of
important factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.

ITEM 2.  PLAN OF OPERATION

During the next twelve months our management intends to actively seek an
operating company to acquire or merge with which may provide operating
revenue.  Based on current economic and regulatory conditions, management
believes that it is possible, if not probable, for a company like ours,
without many assets or liabilities, to negotiate a merger or acquisition with
a viable private company.  The opportunity arises principally because of the
high legal and accounting fees and the length of time associated with the
process of "going public."  However, should a merger or acquisition prove
unsuccessful, it is possible that we may decide not to pursue further
acquisition activities and management may abandon its activities and our
shares would become worthless.

As of the date of this filing, we have not identified any assets or business
opportunities for acquisition.  Potential investors must recognize that
because of limited capital available for investigation of business
opportunities and management's limited experience in business analysis, we may
not discover or adequately evaluate adverse facts about any business
opportunity to be acquired.  All risks inherent in new and inexperienced
enterprises are inherent in our plan.

It is emphasized that our management may effect transactions having a
potentially adverse impact upon our shareholders pursuant to the authority and
discretion of our management to complete acquisitions without submitting any
proposal to the stockholders for their consideration.

As of September 30, 2004 we had $3,198 cash on hand and total current
liabilities of $38,776.  The majority of our operating expenses are related to
our reporting obligations under the Exchange Act.  These expenses include
legal, accounting and professional services required to prepare our reports
and the costs of filing the reports with the SEC.  We are unable to pay cash
for these services and have relied on related parties to pay for these costs
on our behalf.  These parties have not entered into written agreements
guaranteeing advances and, therefore, they are not obligated to provide funds
in the future.  However, management anticipates that these parties will
continue to pay for these costs on our behalf during the next twelve months.
Historically, we have paid for these advances by converting the debt into
common stock.

ITEM 3.  CONTROLS AND PROCEDURES

Our President, who acts in the capacity of principal executive officer and
principal financial officer, has concluded that the disclosures related to the
effectiveness of our disclosure controls and procedures and our internal
control over financial reporting made in our annual report on Form 10-KSB,
filed March 23, 2004, remain accurate.


                                8

<PAGE>

                   PART II:  OTHER INFORMATION

ITEM 6.  EXHIBITS

Part I Exhibits

31.1    Principal Executive Officer Certification
31.2    Principal Financial Officer Certification
32.1    Section 1350 Certification

Part II Exhibits

3.1     Articles of Incorporation as amended  (Incorporated by reference to
        exhibit 3.1 of the Form 10-KSB, filed March 29, 2002)
3.2     Bylaws of Skinovation (Incorporated by reference to exhibit 3.3 of the
        Form-SB, filed July 11, 2000)




                            SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


                                   SKINOVATION PHARMACEUTICAL INCORPORATED


                                    /S/ John W. Peters
Date: November 10, 2004         By: _________________________________________
                                     John W. Peters
                                     President, Principal Executive Officer,
                                     Principal Financial Officer, and Director




                                9